EUVIMEDEUVIMED entdecken
Open Access

Site- and Size-Controlled PEGylation Modulates Biointerfaces and Immunoregulatory Functions of Bifunctional Peptides in an Autoimmune Disease Model

Su Jeong Song iD, Andrea Lucia Villela Nava iD, Jin Xie, Xiaodi Li, Teruna J Siahaan iD, Hyunjoon Kim iD

ACS Applied Materials & Interfaces · 2026

DOI: 10.1021/acsami.5c22267 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2026. Verfasst von Su Jeong Song und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047, United States. Hauptthemen laut MEDLINE: Polyethylene Glycols, Encephalomyelitis, Autoimmune, Experimental, Peptides. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, University of Kansas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoimmune diseases arise from dysregulated autoreactive T cell activation, and current therapies rely on broad immunosuppression that predisposes patients to infection and malignancy. Antigen-specific strategies such as bifunctional peptide inhibitors (BPIs), which couple an antigenic epitope with an ICAM-1-binding sequence to block costimulation, offer promise but remain limited by rapid degradation and insufficient in vivo efficacy. Here, we report a biointerface-engineering strategy based on site- and size-controlled PEGylation to tune the structural presentation and immunomodulatory behavior of BPIs. By systematically varying PEGylation position (N-terminal vs internal spacer) and chain length (1-10 kDa), we identified the spacer-conjugated 5 kDa PEG-BPI conjugate (S-5k) as the optimal configuration balancing bioactivity, dispersion, and immune regulation. The S-5k conjugate demonstrated superior dendritic cell uptake, downregulation of costimulatory markers, and induction of regulatory immune phenotypes both in vitro and in vivo. In the Experimental Autoimmune Encephalomyelitis (EAE) mouse model, treatment with S-5k significantly ameliorated clinical symptoms and promoted immunosuppressive populations, including Foxp3+ Tregs and CD206+ macrophages. Unlike conventional PEGylation used for pharmacokinetic extension, this approach employs PEG as an active spatial modulator of peptide-cell interfaces. Overall, these results establish PEGylation-guided biointerface control as a rational design principle for polymer-peptide conjugates and demonstrate its potential for translational immunotherapy in autoimmune disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polyethylene GlycolsEncephalomyelitis, Autoimmune, ExperimentalPeptidesAnimalsMiceFemaleMice, Inbred C57BLHumansDendritic Cells

Stichwörter der Autor:innen

PEGylated peptideautoimmune diseasebifunctional peptide inhibitor (BPI)experimental autoimmune encephalomyelitis (EAE)immunomodulationsite-specific PEGylation

Substanzen

Polyethylene GlycolsPeptides

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047, United States.

ORCID-Profile: Su Jeong Song, Andrea Lucia Villela Nava, Teruna J Siahaan, Hyunjoon Kim

Förderung

  • NIGMS NIH HHS
  • University of Kansas

Zitieren

APA

Song, S. J., Villela Nava, A. L., Xie, J., Li, X., Siahaan, T. J., & Kim, H. (2026). Site- and Size-Controlled PEGylation Modulates Biointerfaces and Immunoregulatory Functions of Bifunctional Peptides in an Autoimmune Disease Model. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c22267

Vancouver

Song SJ, Villela Nava AL, Xie J, Li X, Siahaan TJ, Kim H. Site- and Size-Controlled PEGylation Modulates Biointerfaces and Immunoregulatory Functions of Bifunctional Peptides in an Autoimmune Disease Model. ACS Applied Materials & Interfaces. 2026. doi:10.1021/acsami.5c22267

BibTeX
@article{Song2026,
  author = {Song, Su Jeong and Villela Nava, Andrea Lucia and Xie, Jin and Li, Xiaodi and Siahaan, Teruna J and Kim, Hyunjoon},
  title = {Site- and Size-Controlled PEGylation Modulates Biointerfaces and Immunoregulatory Functions of Bifunctional Peptides in an Autoimmune Disease Model},
  journal = {ACS Applied Materials & Interfaces},
  year = {2026},
  doi = {10.1021/acsami.5c22267}
}
Kostenlos starten →